Key regions: Australia, Japan, United States, Germany, Europe
The Anti-Coagulants market in Burkina Faso is witnessing a steady growth in recent years.
Customer preferences: Anti-Coagulants are primarily used to prevent blood clots which can lead to serious health issues such as strokes, heart attacks, and deep vein thrombosis. In Burkina Faso, the demand for Anti-Coagulants is driven by the rising prevalence of such health issues, especially among the elderly population. Additionally, the increasing awareness about the benefits of early diagnosis and treatment is also contributing to the growth of the market.
Trends in the market: One of the major trends in the Anti-Coagulants market in Burkina Faso is the shift towards novel oral anticoagulants (NOACs) from traditional anticoagulants such as warfarin. NOACs have several advantages over traditional anticoagulants, including a lower risk of bleeding and the absence of the need for regular monitoring. This trend is expected to continue in the future as more NOACs become available in the market.Another trend that is expected to drive the growth of the Anti-Coagulants market in Burkina Faso is the increasing use of combination therapies. Combination therapy involves the use of two or more drugs to achieve better treatment outcomes. In the case of Anti-Coagulants, combination therapy is used to reduce the risk of blood clots and prevent bleeding.
Local special circumstances: Burkina Faso is a low-income country with limited healthcare infrastructure. The availability of Anti-Coagulants is limited in the country, and the cost of treatment can be a barrier for many patients. However, the government has taken several initiatives to improve access to healthcare services, including the provision of free healthcare for children under the age of five and pregnant women. Additionally, the government has also implemented a national health insurance scheme to provide affordable healthcare services to the population.
Underlying macroeconomic factors: The healthcare sector in Burkina Faso is expected to grow in the coming years, driven by increasing government spending on healthcare infrastructure and the rising demand for healthcare services. However, the country still faces several challenges, including a shortage of healthcare professionals and limited access to healthcare services in rural areas. Additionally, the COVID-19 pandemic has had a significant impact on the healthcare sector in Burkina Faso, leading to a disruption in healthcare services and a decline in healthcare spending. Despite these challenges, the Anti-Coagulants market in Burkina Faso is expected to continue its growth trajectory in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
